As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI® (metoclopramide) is uniquely positioned to address the ongoing needs of patients ...
Evoke Pharma (NASDAQ:EVOK) shares rocketed 90% early Monday on positive data for its nasal drug Gimoti in the treatment of ...
Stock analysts at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report issued on Saturday. The brokerage set a “sell” rating on the specialty ...
Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® ...
StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report released on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback